Daniel R. Kimbell

Daniel R. Kimbell

Pasadena Office
119 E. Union St., Suite B
Pasadena, CA 91103

+1 (213) 785-8073 Phone
(213) 995-5010 Fax

Attorney

Education

Loyola Law School, Los Angeles, J.D.
University of California, Los Angeles, BS, Chemistry

Bar Memberships: California and Washington State

 

 

Experience

Dan is an AV rated and has been a patent and trademark prosecution and licensing attorney for over 30 years,  Over the course of his career has prosecuted and secured well over a 1,000 patents and thousands of trademarks in a wide variety of technical and business areas.  In 2013 he earned the prestigious Certified Licensing Professional® (CLP) credential.  The CLP credential acknowledges licensing professionals who have demonstrated the highest experience and proficiency in licensing and the commercialization of intellectual property and is built on internationally applicable standards of practice, knowledge, and ethics.

Dan is skilled in handling and advising companies on how to best leverage IP to improve their businesses and executes on the steps needed to accomplish client goals.

Most patent attorneys have never personally started a technology company and thus don’t fully understand the challenges faced by high tech entrepreneurs.  Dan has co-founded four startup companies.  One is Emmaus Life Sciences, Inc. (www.emmausmedical.com), a pharmaceutical company which he co-founded in 2000 and ran as its COO for 10 years.  During his tenure, Emmaus ran important clinical trials in the area of sickle cell disease, in-licensed and marketed third party pharmaceuticals, and began its maturation and groundwork to become a fully-fledged pharmaceutical company.  In July 2017 the company’s New Drug Application for Endari® (L-glutamine oral powder) for treating sickle cell anemia and sickle beta-0 thalassemia was approved by the FDA.  At the time of the approval, Endari® was the first new sickle cell disease drug in 20 years and the first ever drug for children.  Endari® is being sold in the U.S. and efforts are in the works to expand drug marketing approval in other countries.